Cargando…
Epstein-barr Virus Negative Primary Central Nervous System Lymphoma Developed after Treatment of Glioblastoma: A Case Report
Temozolomide is an oral alkylating agent with moderate side effects compared to other agents. However, the development of secondary malignancies following temozolomide has been reported. We describe the first case of primary central nervous system lymphoma (PCNSL) occurrence following glioblastoma t...
Autores principales: | KHAIRUNNISA, Novita Ikbar, YAMASAKI, Fumiyuki, AMATYA, Vishwa Jeet, TAKAYASU, Takeshi, YONEZAWA, Ushio, TAGUCHI, Akira, ONISHI, Shumpei, HORIE, Nobutaka |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japan Neurosurgical Society
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719745/ https://www.ncbi.nlm.nih.gov/pubmed/36518906 http://dx.doi.org/10.2176/jns-nmc.2022-0228 |
Ejemplares similares
-
MET-8 EFFECT OF VEGF-TARGETED THERAPY FOR SYMPTOMATIC/REFRACTORY BRAIN EDEMA CAUSED BY METASTATIC BRAIN TUMORS
por: Fumiyuki, Yamasaj, et al.
Publicado: (2022) -
COT-11 Relationship between preoperative liquid biopsy and prognosis of glioblastoma -Next Generation Sequencing of small noncoding RNA-
por: Onishi, Shumpei, et al.
Publicado: (2021) -
COT-04 Circulating biomarker for glioblastoma and primary central nervous system lymphoma -Next Generation Sequencing of small noncoding RNA-
por: Onishi, Shumpei, et al.
Publicado: (2020) -
Effect of bevacizumab against cystic components of brain tumors
por: Yamasaki, Fumiyuki, et al.
Publicado: (2019) -
COT-17 EFFECT OF BEVACIZUMAB AGAINST CYSTIC COMPONENT OF PRIMARY/METASTATIC BRAIN TUMORS
por: Yamasaki, Fumiyuki, et al.
Publicado: (2019)